Nuclear factor one B (NFIB) encodes a subtype-specific tumour suppressor in glioblastoma

31Citations
Citations of this article
48Readers
Mendeley users who have this article in their library.

Abstract

Glioblastoma (GBM) is an essentially incurable and rapidly fatal cancer, with few markers predicting a favourable prognosis. Here we report that the transcription factor NFIB is associated with significantly improved survival in GBM. NFIB expression correlates inversely with astrocytoma grade and is lowest in mesenchymal GBM. Ectopic expression of NFIB in low-passage, patient-derived classical and mesenchymal subtype GBM cells inhibits tumourigenesis. Ectopic NFIB expression activated phospho-STAT3 signalling only in classical and mesenchymal GBM cells, suggesting a mechanism through which NFIB may exert its context-dependent tumour suppressor activity. Finally, NFIB expression can be induced in GBM cells by drug treatment with beneficial effects.

Cite

CITATION STYLE

APA

Stringer, B. W., Bunt, J., Day, B. W., Barry, G., Jamieson, P. R., Ensbey, K. S., … Richards, L. J. (2016). Nuclear factor one B (NFIB) encodes a subtype-specific tumour suppressor in glioblastoma. Oncotarget, 7(20), 29306–29320. https://doi.org/10.18632/oncotarget.8720

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free